Cases

PRECEDENTIAL UNITED STATES COURT OF APPEALS FOR THE THIRD CIRCUIT No. 18-2621 FEDERAL TRADE COMMISSION, Appellant v. ABBVIE INC; ABBOTT LABORATORIES; UNIMED PHARMACEUTICALS, LLC; BESINS HEALTHCARE, INC.; *TEVA PHARMACEUTICALS USA, INC (*Dismissed Pursuant to Court’s 3/12/19 Order.) No. 18-2748 FEDERAL TRADE COMMISSION,

2021 IL App (1st) 200527 FIFTH DIVISION MARCH 31, 2021 No. 1-20-0527 CASTLERIGG MASTER INVESTMENTS, LTD., ) Appeal from the ) Circuit Court of Plaintiff-Appellant, ) Cook County.

PRECEDENTIAL UNITED STATES COURT OF APPEALS FOR THE THIRD CIRCUIT No. 18-2621 FEDERAL TRADE COMMISSION, Appellant v. ABBVIE INC.; ABBOTT LABORATORIES; UNIMED PHARMACEUTICALS, LLC; BESINS HEALTHCARE, INC.; *TEVA PHARMACEUTICALS USA, INC. (*Dismissed Pursuant to Court’s 3/12/19 Order.) No. 18-2748 FEDERAL TRADE COMMISSION

Digitally signed by Reporter of Decisions Reason: I attest to Illinois Official Reports the accuracy and

DYK, Circuit Judge. The Mathilda and Terrance Kennedy Institute of Rheumatology Trust (Kennedy) owns U.S. Patent Nos. 7,846,442 (the '442 patent) and 6,270,766 (the '766 patent). Both patents are directed towards methods of treating rheumatoid arthritis by co-administering two drugs. AbbVie, Inc. and AbbVie Biotechnology Ltd. (collectively, AbbVie) are licensees of the '766 pa

FINDINGS OF FACT AND CONCLUSIONS OF LAW PAUL A. CROTTY, District Judge: TABLE OF CONTENTS FINDINGS OF FACT...........................................................434 I. THE PARTIES.........................................................434 II. II. RHEUMATOID ARTHRITIS AND ITS TREATMENT ..................434 A. R

Case: 24-1965 Document: 76 Page: 1 Filed: 01/29/2025 United States Court of Appeals for the Federal Circuit ______________________ REGENERON PHARMACEUTICALS, INC., Plaintiff-Appellee v. MYLAN PHARMACEUTICALS INC., AMGEN USA, INC., BIOCON BIOLOGICS INC., CELLTRION, INC., FORMYCON AG, AMGEN INC., Defendants SAMSUNG BIOEPIS CO., LTD., Defendant-A

Prost, Chief Judge, dissenting. Because I believe that the district court clearly erred when it found there would not have been a reasonable expectation of success in selecting unsubstituted benzyl for R and unsubstituted methyl for R1, I disagree with the majority that the asserted claims of the '551 patent are patentably distinct from the reference patent claims. I therefore respectfully dissent. I<

PRELIMINARY PRINT Volume 598 U. S. Part 2 Pages 594–616 OFFICIAL REPORTS OF THE SUPREME COURT May 18, 2023 Page Proof Pending Publication REBECCA A. WOMELDORF reporter of decisions NOTICE: This preliminary print is subject to formal revision before the bound volume is published. Users are requ

OPINION STARK, United States District Judge: Plaintiffs — UCB, Inc., UCB BioPharma SPRL, Research Corporation Technologies, Inc., and Harris FRC Corporation (collectively, “Plaintiffs”) — allege that Defendants — Accord Healthcare, Inc., Intas Pharmaceuticals Ltd., Alembic Pharmaceuticals, Ltd., Amneal Pharmaceuticals LLC, Amneal Pharmaceuticals of New York, LLC, Aurobindo Pharma Ltd., Auro-bindo Pharma USA,

22-0427-cv Regeneron Pharmaceuticals, Inc. v. Novartis Pharma AG In the United States Court of Appeals for the Second Circuit August Term 2023 No. 22-0427-cv REGENERON PHARMACEUTICALS, INC., Plaintiff-Appellant, v.

IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE TRIFECTA MULTIMEDIA HOLDINGS ) INC., and DAVE YOUNG, ) ) Plaintiffs, ) ) v. ) C.A. No. 2023-0699-JTL ) WCG CLINICAL SERVICES LLC, )

Newman, Circuit Judge. This appeal is from the dismissal of a declaratory judgment action filed by AIDS Healthcare Foundation, Inc. ("Healthcare" or "AHF") against Gilead Sciences, Inc. et al. ("Defendants") in the United States District Court for the Northern District of California. 1 On appellate review,

MEMORANDUM OPINION AND ORDER AMY J. ST. EVE, District Court Judge: In this patent infringement action, The Medicines Company (“TMC”) asserts that Defendants’ proposed generic bivalirudin drug product infringes United States Patent No. 7,582,727 (the “’727 patent”). Specifically, TMC claims that Defendants Mylan, Inc., Mylan Pharmaceuticals Inc. and Bioniche Pharma USA, LLC (collectively, “Mylan

MEMORANDUM AND ORDER Wolf, District Judge. This Memorandum is based on the transcript of the decision rendered orally on August 18, 2016, allowing defendants Cell-*366trion Healthcare Co., Ltd., Celltrion, Inc., and Hospira, Inc.’s, Motion For Summary Judgment Of Invalidity Of Claims 1, 3, 5, 6, 7 Of The '471 patent For Obviousness-Type Double Pate

AMENDED TRIAL OPINION ANDREWS, UNITED STATES DISTRICT JUDGE Plaintiffs brought these patent infringement actions against Breckenridge Pharmaceutical, Inc., Roxane Laboratories, Inc.1, and Par Pharmaceutical, Inc. in 2014. (D.I. l).2 Breckenridge, Roxane, and Par each filed an Abbreviated New Drug Application (“ANDA”), seeking to engage in the commerci

SYLLABUS This syllabus is not part of the Court’s opinion. It has been prepared by the Office of the Clerk for the convenience of the reader. It has been neither reviewed nor approved by the Court and may not summarize all portions of the opinion. Alison Beavan v. Allergan U.S.A., Inc. (A-53-24) (090150) Argued January 22, 2026 -- Decided May 27, 2026 JUSTICE PATTERSON, writing for a unanimous Court. This appeal concerns expert testim

FILED UNDER SEAL MEMORANDUM OPINION STARK, United States District Judge: Bayer Pharma AG, Bayer Intellectual Property GmbH, and Bayer Healthcare Pharmaceuticals Inc. (collectively, “Bayer” or “Plaintiffs”) allege that Watson Laboratories, Inc. (“Watson” or “Defendant”) infringes United States Patent No. 8,071,577 (“the ’577 patent” or “the patent-in-suit”). (D.I. 1) The ’577 patent rel

MEMORANDUM OPINION AND ORDER MATTHEW F. KENNELLY, District - Judge: Background On June 26, 2014, Don Estep, a citizen of Texas, sued the following entities in Illinois state court: 1) AbbVie Inc. & Abbott Laboratories (collectively AbbVie), whose principal place of business is in Illinois; 2) Pharmacia & Upjohn Co., Inc., whose principal place of business is in

Royce C. Lamberth, United States District Judge *89I. Background Before the Court is a trio of actions brought under 35 U.S.C. § 145, related to three of Gilbert Hyatt's applications to patent features of his "600